Chronic Wounds

Chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure injuries, and arterial ulcers, affect approximately 6.5 million individuals in the United States annually, often resulting from restricted blood perfusion that impedes healing. Zhittya Genesis Medicine is developing a treatment utilizing human Fibroblast Growth Factor 1 (FGF-1) to promote therapeutic angiogenesis—the formation of new blood vessels—to enhance blood supply and facilitate healing in affected areas. Previous Phase II clinical trials have demonstrated that FGF-1 can significantly accelerate the healing of chronic wounds, with studies reporting complete closure in all treated diabetic foot ulcers and more than doubled healing rates in venous leg ulcers, without serious adverse events. Recognizing the substantial unmet medical need, Zhittya aims to advance this innovative therapy through clinical development, potentially qualifying for the U.S. FDA's "Medical Breakthrough Therapy" designation. Read more in our white paper below: